

SALINAN

PRES I DEN REPMBLIK I NDO NESIA

PRESIDENTIAL REGULATION OF THE REPUBLIC

OF INDONESIA NUMBER 101 OF 2021

ABOUT

THE IMPLEMENTATION OF PATENTS BY THE GOVERNMENT AGAINST

THE DRUG FAVIPTRAVIR

BY THE GRACE OF GOD ALMIGHTY THE

PRESIDENT OF THE REPUBLIC OF INDONESIA,

Weigh

- a. that the spread of *Corona* Uirus *Disease* !2019 (COVID-19) has been declared by the *World Health Organization* (WHO) as a *global* pondemic and the Government has also designated the non-natural disaster of the spread of Corono **Virus** *Disea: se* 2019 (COVID-19) as a national disaster:
- b. that in connection with the very urgent need in efforts to combat *Corona Virus Disease 2019* (COVID-19J in Indonesia), it is necessary to establish an access policy to Favipiravir drugs that are currently still protected by patents;
- C. that based on the provisions of Article 109 paragraph (3) of Law No. 13 of 2016 on Patents asamended by Law No. 11 of 2020 on Work Copyright, The Implementation of Patents by the Government is stipulated by Presidential Regulation;
- d. that based on the considerations referred to in letter a, letter b, and letter c, it is necessary to establish a Presidential Regulation on the Implementation of Patents by the Government on the Drug Favipiravir;
- 1. Article 4 paragraph (1) of the Constitution of the Republic of Indonesia of 1945;

Remember

2. The law...



PRES IDEHI REPUBLIK I ND0 NES IA

- 2 -

2. Law No. 13 of 2016 on Patents (State Gazette of the Republic of Indonesia year 2010 Number 176, Supplementary State Gazette of the Republic of Indonesia Number 5922) as amended by Law No. 11 of 2020 on Cipta Kerja (State Gazette of the Republic of Indonesia Year2020 Number 245, Supplementary State Gazette of the Republic of Indonesia Number 6573);

DECIDE:

SET

THE PRESIDENTIAL REGULATION ON THE IMPLEMENTATION OF PATENTS BY THE GOVERNMENT AGAINST THE DRUG FAVIPIRAVIR.

Article 1

- (1) The government carries out patents on drugs.
 Favipiravir.
- (2) The implementation of patents by the Government on the drug Favipiravir is intended to meet the availability and urgent need for the treatment of Corona Virus Disea: se 201 9 (COVID-19).
- (3) The implementation of patents by the Government on the drug Favipiravir is carried out for a period of 3 (three) years since this Presidential Regulation came into force.
- (4) If after a period of 3 (three) years as referred to in paragraph (3) the pandemic has not ended, the implementation of the patent by the Government is extended until the Pandemic Coronn *Viru:s Disea:se 2019* (COVID-19) is set to expire by the Government.

Article 2

The implementation of patents by the Government on the drug Favipiravir as referred to in Article 1 paragraph (1) contains the name of the active substance, the name of the patent holder, the patent application number / patent number, and the title of the invention as stated in the Annex which is an integral part of this Presidential Regulation.

Article 3...



PRES I DEN REPUBLIK I NDO NESIA

Article 3

- (1) The Minister who organizes government affairs in the health sector appoints the pharmaceutical industry as the executor of the Favipiravir drug patent as referred to in Article 1 paragraph (1) for and on behalf of the Government in accordance with the provisions of the laws and regulations.
- (2) The pharmaceutical industry as referred to in paragraph (1) carries out its duties as the executor of Favipiravir drug patents on a limited basis, to meet domestic needs, and is noncommercial.
- (3) The pharmaceutical industry as referred to in paragraph(1) shall meet the requirements:
 - a. have facilities and are able to carry out patents;
 - b. not transferring the implementation of the patent to another party; and
 - c. have a good way of production, circulation, and supervision in accordance with the provisions of the laws and regulations.

Article 4

The pharmaceutical industry as referred to in Article 3 provides a reward to patent holders of 1% (one percent) of the net selling value of the drug Favipiravir.

Article 5

- (1) The reward as referred to in Article 4 is carried out annually.
- (2) Reward as referred to in the verse
 (1) it is carried out in accordance with the period of time referred to in Article 1 paragraph (3) and paragraph (4).

Article O

This Presidential Regulation comes into effect on the date it is promulgated.

In order to...



PRES I DEN REPUBLIK I CDO NESIA

In order for everyone to know, order the promulgation of this Presidential Regulation with its placement in the State Gazette of the Republic of Indonesia.

> Set in Jakarta November 10, 2021

PRESIDENT OF THE REPUBLIC OF INDONESIA,

ttd.

JOKO WIDODO

Diundangkan in vJakarta On November 10, 202 l

MINISTER OF LAW AND HUMAN RIGHTS OF THE REPUBLIC OF INDONESIA,

ttd.

YASONNA H. LAOLY

STATE GAZETTE OF THE REPUBLIC OF INDONESIA YEAR 202 1 NUMBER 254

Copies in accordance with the original MINISTRY OF STATE SECRETARIAT OF THE REPUBLIC OF INDONESIA

De dEng Legislation and Legal SEKREMAN Administration,



PRES I DEC REPLI BLIK I NDO NESIA

ATTACHMENT

PRESIDENTIAL REGULATION OF THE REPUBLIC

OF INDONESIA NUMBER 101 OF 2021

ABOUT

IMPLEMENTATION OF PATENTS BYTHE

GOVERNMENT ON THE DRUG

FAVIPIRAVIR

NAME OF ACTIVE SUBSTANCE, NAME OF PATENT HOLDER, PATENT APPLICATION NUMBER/ PATENT NUMBER, AND TITLE OF INVENTION

| No | NAME OF ACTIV E SUBS TANC E | NAME OF PATENT HOLDER | PATENT APPLICATION NUMBER/ NUMBER PATENT | TITLE OF INVENTION |
|----|---|------------------------------------|--|--|
| 1. | Favipiravir | Fujifilm Toyama Chemical Co., Ltd. | W0020 1000982/ IDP0032152 W00201301813/ IDP000045023 W00201301812/ IDP000040569 | Organic Amina Salt from 6-F1uoro-3- Hydroxy-2- Pirazincarbonile and Its Manufacturing Method Sodium Salt from 6— Fluoro—3-Hydroxy—2— Pyrrazina Carboxamide Meglumina salt from 6-Fluoro-3-Hydroxy-2- Pyrrazin Carboxamide |

| 四日之 | 3 |
|--------|----------------|
| | |
| S. | |
| TO (I) | All the second |

| W0020 1103243/ IDP000046 140 | Insulated Tablets and Powders Contains 6-F1uoro- 3- Hydroxy-2- Pirazinakarbokididide |
|---------------------------------------|--|

W002009O2268.



PRES I DEN REPUBLIC OF INDONESIA

- 2 -

| | W00200902268/ IDP000034309 | Pharmaceutical Composition Containing |
|--|-------------------------------|--|
| | 1DP000034309 | Pyrrazin Derivatives, and Methods of Use of Pirazin Derivatives in |
| | | Combined |

PRESIDENT OF THE REPUBLIC OF INDONESIA,

Ltd..

JOKO WIDODO

Copies in accordance with the original MINISTRY OF STATE SECRETARIAT OF THE REPUBLIC OF INDONESIA

ang Legislation and Andread democracy,

Silvanna Djaman